{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:18:55Z","timestamp":1781101135676,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":463,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1093\/annonc\/mdy146","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:09:53Z","timestamp":1524150593000},"page":"iv41-iv50","source":"Crossref","is-referenced-by-count":73,"special_numbering":"S4","title":["Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"29","author":[{"given":"E.","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Staber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy146_bb0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988\u20131994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdy146_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2007.02.002","article-title":"The incidence and survival of Waldenstrom's macroglobulinaemia in South East England","volume":"32","author":"Phekoo","year":"2008","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdy146_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdy146_bb0025","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdy146_bb0030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/sonc.2003.50063","article-title":"Familial Waldenstrom's macroglobulinemia","volume":"30","author":"McMaster","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2012.08.006","article-title":"Familial disease predisposition impacts treatment outcome in patients with Waldenstrom macroglobulinemia","volume":"12","author":"Treon","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdy146_bb0050","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2008-06-162768","article-title":"Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia patients: a population-based study in Sweden","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0060","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","volume":"2","year":"2017"},{"key":"10.1093\/annonc\/mdy146_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/leu.2013.124","article-title":"Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's macroglobulinemia: new criteria for differential diagnosis and risk stratification","volume":"28","author":"Paiva","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdy146_bb0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy146_bb0075","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to ibrutinib in Waldenstrom's macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy146_bb0080","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2014.65","article-title":"Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"28","author":"Xu","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdy146_bb0085","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13078","article-title":"MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome","volume":"167","author":"Poulain","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0090","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy146_bb0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0100","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0105","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1373\/clinchem.2009.124461","article-title":"Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry","volume":"55","author":"Murray","year":"2009","journal-title":"Clin Chem"},{"key":"10.1093\/annonc\/mdy146_bb0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom macroglobulinaemia: a task force from the 8th International Workshop on Waldenstrom Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0120","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1093\/annonc\/mdy146_bb0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3816\/CLM.2009.n.027","article-title":"Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's macroglobulinemia","volume":"9","author":"Menke","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdy146_bb0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.2005.071175","article-title":"Peripheral neuropathies in Waldenstrom's macroglobulinaemia","volume":"77","author":"Levine","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1093\/annonc\/mdy146_bb0140","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00415-014-7612-4","article-title":"Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study","volume":"262","author":"Vlam","year":"2015","journal-title":"J Neurol"},{"key":"10.1093\/annonc\/mdy146_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2016.08.013","article-title":"Monoclonal IgM-related AL amyloidosis","volume":"29","author":"Milani","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0150","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ajh.22044","article-title":"The role of 18F-FDG PET\/CT imaging in Waldenstrom macroglobulinemia","volume":"86","author":"Banwait","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdy146_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0165","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy146_bb0170","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom's macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases","volume":"115","author":"Garcia-Sanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0180","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0185","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0190","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0195","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0200","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2032flare\u2032 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdy146_bb0205","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdy146_bb0215","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0220","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdy146_bb0225","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0230","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1080\/10428194.2017.1307357","article-title":"A phase II Bayesian sequential clinical trial in advanced Waldenstrom macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone","volume":"58","author":"Leblond","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdy146_bb0235","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0245","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy146_bb0250","first-page":"2767","article-title":"Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia","volume":"130","author":"Treon","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0255","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdy146_bb0260","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0265","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy146_bb0270","first-page":"2026","volume":"130","author":"Kyriakou","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy146_bb0275","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214)","volume":"23","author":"Treon","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy146_bb0280","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: results of WMCTG trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy146_bb0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3816\/CLM.2009.n.019","article-title":"Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia","volume":"9","author":"Chen","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdy146_bb0290","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdy146_bb0295","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy146_bb0300","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdy146_bb0305","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/Supplement_4\/iv41\/27689694\/mdy146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:47:48Z","timestamp":1624682868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419316953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":60,"alternative-id":["S0923753419316953"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy146","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}